

ASTRAZENECA PLC
Form 6-K
July 30, 2003

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For July 2003

Commission File Number: 001-11960

AstraZeneca PLC

15 Stanhope Gate, London W1K 1LN, England

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

AstraZeneca PLC

INDEX TO EXHIBITS

1. Press release entitled, AstraZeneca PLC appoints two new non-executive directors , dated 1 July 2003.

2. Press release entitled, "Dealing by Directors", dated 8 July 2003.
 3. Press release entitled, "FDA Advisory Committee unanimously recommends approval of Crestor® (rosuvastatin calcium)", dated 10 July 2003.
 4. Press release entitled, "Exanta (ximelagatran) shows efficacy in first study for treatment of venous thromboembolism (VTE) - supports regulatory submission", dated 14 July 2003.
 5. Press release entitled, "Front half of AstraZeneca PLC Second Quarter and Half Year Results 2003", dated 24 July 2003.
 6. Press release entitled, "Second half of AstraZeneca PLC Second Quarter and Half Year Results 2003", dated 24 July 2003.
-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 July 2003

By: /s/ G H R Musker

Name: G H R Musker

Title: Company Secretary & Solicitor

Item 1

ASTRAZENECA PLC APPOINTS TWO NEW

NON-EXECUTIVE DIRECTORS

AstraZeneca PLC today announced that two new Non-Executive Directors are to join the Board of Directors with immediate effect.

They are Ms. Michele Hooper, formerly President and Chief Executive Officer of Stadlander Drug Company in the US and earlier with Baxter, and Mr Joe Jimenez, President and Chief Executive Officer of Heinz Europe.

Mr. Percy Barnevik, Chairman of AstraZeneca, said: "I am very pleased that Michele Hooper and Joe Jimenez are joining us. Michele brings considerable experience of the US healthcare industry and Joe has expertise in brand development and consumer marketing both in the US and Europe. This experience will add great benefit to the work of the Board."

1 July 2003

Media Enquiries:

Emily Denney, Tel: +44 (0) 207 304 5034

Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:

Mina Blair Robinson, Tel: +44 (0) 207 304 5084

Jonathan Hunt, Tel: +44 (0) 207 304 5087

NOTE TO NEWS EDITORS:

The biographical details of Ms. Hooper and Mr. Jimenez are as follows:

Ms Michele J Hooper (51)

Business experience

Stadtlander Drug Company

President and CEO (1998 - 1999)

Baxter (including Baxter spin-offs) (1976 -1998)

Caremark International (Now Medpartners Inc.)

Corporate VP And President International Businesses (1992 - 1998)

Alternate Site International

President (1991 - 1992)

Baxter Healthcare Corp.

President Canada (1988 - 1991)

Baxter International, Inc.

VP Corporate Planning (1984 - 1998)

Baxter Healthcare Corp.

Various Management Positions (1976 - 1984)

Current Boards

PPG Industries, Inc.

Target Corporation

Davita Inc.

Mr Joe Jimenez (42)

Business Experience

H J Heinz Company

° Executive Vice President, President and Chief Executive Officer
Heinz Europe (2002 to present)

° Senior Vice President and President Heinz North America (2001 -
2002)

° Corporate Vice President and President Heinz North America
(1998 - 2001)

Conagra

- ° President Hunt Wesson/Peter Pan & Orville Redenbacher/Swiss Miss Food Cos. (1997 - 1998)
- ° Various positions including Senior Vice President Marketing, Orville Redenbacher/Swiss Miss & Vice President Marketing, La Choy / Rosarita & Vice President Orville Redenbacher Popcorn (1993 - 1997)

Clorox Company

- ° Senior Marketing Officer (1984 - 1993)

Current Boards

Hain Celestial Group, Inc.

- Ends -

Item 2

DEALING BY DIRECTORS
COMPANIES ACT 1985 SECTIONS 324/329

WE HEREBY INFORM YOU THAT, ON 7 JULY 2003, SIR TOM MCKILLOP, A DIRECTOR OF THE COMPANY, ACQUIRED AN INTEREST IN 61 ASTRAZENECA PLC ORDINARY SHARES OF USD0.25 EACH AT A PRICE OF 2439 PENCE PER SHARE. THE INTEREST ARISES AS A RESULT OF THE AUTOMATIC ANNUAL ACQUISITION OF ASTRAZENECA SHARES BY EMPLOYEES PARTICIPATING IN THE COMPANY'S PARTNERSHIP SHARE ARRANGEMENTS. PARTNERSHIP SHARES ARE ACQUIRED AND HELD ON BEHALF OF PLAN PARTICIPANTS BY ASTRAZENECA EMPLOYEE SHARE TRUST LIMITED UNDER THE TERMS OF THE ASTRAZENECA ALL EMPLOYEE SHARE PLAN, WHICH IS OPEN TO ALL UK EMPLOYEES OF THE COMPANY. FOLLOWING THIS ACQUISITION, SIR TOM MCKILLOP HAS A TOTAL INTEREST IN 69,560 ORDINARY SHARES, WHICH REPRESENTS APPROXIMATELY 0.004 PER CENT OF THE NUMBER OF SHARES CURRENTLY IN ISSUE.

G H R MUSKER
COMPANY SECRETARY
8 JULY 2003

Item 3

**FDA ADVISORY COMMITTEE UNANIMOUSLY RECOMMENDS
APPROVAL OF CRESTOR® (rosuvastatin calcium)**

AstraZeneca announced today that the Endocrinologic and Metabolic Advisory Committee to the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval for CRESTOR® (rosuvastatin calcium) as an adjunct to diet for the treatment of various lipid disorders including hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. The FDA will now review the Committee's recommendation and make its final decision on granting marketing approval for CRESTOR.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

The Committee's unanimous recommendation to approve CRESTOR represents a vote of confidence in the clinical profile of CRESTOR, said Howard Hutchinson, Vice President of Clinical Research, AstraZeneca. We believe that once approved, CRESTOR will provide patients who are untreated or not at their target cholesterol levels with an important new treatment option in the control of elevated cholesterol.

The clinical development programme for CRESTOR is the largest pre-approval programme ever submitted to evaluate the safety and efficacy of a new statin. More than 12,500 patients are included in the safety database with more than 4,000 patients exposed to the 40 mg dose. The most commonly reported treatment-related adverse events were myalgia, abdominal pain, nausea and asthenia.

CRESTOR belongs to the class of lipid-lowering medications called HMG- CoA reductase inhibitors, or statins and has been studied in more than 24,000 patients worldwide. CRESTOR is being studied in an extensive clinical outcomes programme known as GALAXY, which includes more than 19,000 patients from 23 countries.

AstraZeneca licensed worldwide rights to CRESTOR from the Japanese pharmaceutical company Shionogi & Co., Ltd. CRESTOR was first approved in the Netherlands in 2002 and approval has recently been granted in 23 other countries. Launches have occurred in a number of countries, including Canada, the Netherlands and the United Kingdom.

AstraZeneca (AZN: NYSE) is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over \$17.8 billion and leading positions in sales of cardiovascular, gastrointestinal, oncology, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

10 July 2003

Media Enquiries:

Emily Denney, Tel: +44 (0) 207 304 5034

Steve Brown, Tel: +44 (0) 207 304 5033

Gary Bruell, Tel: +1 302-885-1554

Rachel Bloom-Baglin, Tel: +1 302-886-7858

Investor Relations:

Mina Blair Robinson, Tel: +44 (0) 207 304 5084

Jonathan Hunt, Tel: +44 (0) 207 304 5087

- Ends -

Item 4

EXANTA™ (ximelagatran) SHOWS EFFICACY IN FIRST STUDY FOR TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) SUPPORTS REGULATORY SUBMISSION

AstraZeneca announced today that data from the *THRIVE Treatment* study show that Exanta™ (ximelagatran), the first in a new class of oral anticoagulants called oral direct thrombin inhibitors (oral DTIs), is as effective as the current standard of care treatment regimen, enoxaparin/warfarin, in the treatment of acute venous thromboembolism (VTE; deep vein thrombosis with or without pulmonary embolism) and secondary prevention of recurrent VTE events. Importantly, the six month long study, presented today at the XIX Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Birmingham, UK, also showed a favourable trend for Exanta in bleeding and mortality rates compared with the standard therapy regimen.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

THRIVE Treatment, an international, randomised, multicentre, double-blind study, was designed as a non-inferiority study to compare fixed dose oral Exanta 36mg twice daily with the current standard treatment, enoxaparin (1mg/kg) followed by dose-adjusted warfarin (INR 2.0-3.0). The primary endpoint of the study was achieved, demonstrating the equivalent efficacy of oral Exanta to the standard treatment regimen in the prevention of recurrent VTE over six months. The incidence of recurrent VTE events was 26 Exanta vs 24 enoxaparin/warfarin (estimated cumulative risk 2.1% vs 2.0%), in the ITT (Intention To Treat) analysis.

The impact of thrombosis is often underestimated, despite the fact that it is the third most common cardiovascular disease worldwide, affecting over five million people each year, said Dr. Hamish Cameron, Vice President, Head of Exanta, AstraZeneca.

The results of *THRIVE Treatment* complement the earlier findings of *THRIVE III*, and further demonstrate the promise of Exanta to be at least as effective as the best type of standard treatment currently available. These studies will form the basis for the regulatory submission for Exanta in the treatment and long-term prevention of VTE, which remains on track for late this year.

Safety and mortality outcomes also showed a favourable trend for Exanta over enoxaparin/warfarin with respect to the risk of major bleeding: 14 Exanta vs 25 standard treatment, (estimated cumulative risk 1.3% vs 2.2%) in the OT (On Treatment) analysis and all-cause mortality: 28 Exanta vs 42 standard treatment, (estimated cumulative risk 2.3% vs 3.4%), ITT analysis.

Laboratory blood tests in the study showed an incidence of liver enzyme elevations in 9.6% of patients receiving Exanta, compared with 2% of patients receiving enoxaparin/warfarin. These elevations decreased spontaneously whether treatment continued or was stopped. As has been seen in previous studies, these elevations were typically transient and not associated with any specific clinical symptoms.

Patients taking Exanta benefit from at least as effective anti-thrombotic protection as those treated with well-controlled warfarin, but without the limitations of warfarin treatment or its requirement for time and cost-intensive coagulation monitoring and dose titration. These promising efficacy results need to be considered alongside the safety profile for Exanta emerging from this study and from other clinical trials, which will define its overall benefit-risk profile.

Exanta has completed phase III studies in a number of indications and is the first oral anticoagulant to reach late stage clinical trials since the development of warfarin more than 50 years ago. To date more than 30,000 patients have been enrolled in the Exanta clinical trial programme. Of the 17,000 patients who have been treated with Exanta, over a third (7,000) have received Exanta treatment for at least six months. The current worldwide market for anti-thrombotics is \$9.6 billion.

Exanta is being reviewed in Europe for the prevention of venous thromboembolism (VTE) following elective hip or knee replacement surgery and will be submitted for regulatory approval in the US for the same indication in Q4 2003. In addition to the regulatory submission for the treatment of VTE, scheduled for submission in Europe in the fourth quarter of this year, submissions in the EU and US for the prevention of stroke in atrial fibrillation patients are also planned for the 4Q of 2003.

Exanta is a trademark of the AstraZeneca group of companies.

14 July 2003

Media Inquiries:

Steve Brown, +44 (0) 207 304 5033
Emily Denney, +44 (0) 207 304 5034

Investor Inquiries:

Mina Blair-Robinson, +44 (0) 207 304 5084
Jonathan Hunt, +44 (0) 207 304 5087

Editors Notes:

The *THRIVE Treatment* study was established from study groups from the *THRIVE II & V* studies.

The **THR**ombin Inhibitor in **V**enous thrombo**E**mbolism (*THRIVE Treatment*) study involved 2,489 patients with acute deep vein thrombosis (DVT), of whom 37% had confirmed pulmonary embolism. Patients were randomly assigned to, and received, either oral ximelagatran 36mg bid for six months, or subcutaneous enoxaparin 1mg/kg bid for a minimum of five days followed by warfarin (target INR of 2.0-3.0) for six months.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

The rationale for non-inferiority studies: As many highly effective treatments are available in various therapeutic areas, placebo-controlled trials are often now considered unethical. Therefore, the concept of non-inferiority testing is increasingly common where the objective of these studies is to demonstrate that a treatment is not inferior to or 'as effective as' a gold standard treatment. This can then enable treatments to be differentiated in terms of their respective additional advantages to the patient and physician, such as convenience or benefit-risk. Exanta met the non-inferiority criterion in the *THRIVE Treatment* study.

- Ends -

Item 5

AstraZeneca PLC Second Quarter and Half Year Results 2003

First half results ahead of expectations. Interim dividend increased by 10 percent. EPS targets for the year increased.

Financial Highlights

| Group | 2 nd Quarter | | Actual % | CER % | Half Year | | Actual % | CER % |
|--------------------|-------------------------|---------|----------|-------|-----------|---------|----------|-------|
| | 2003 | 2002 | | | 2003 | 2002 | | |
| | \$m | \$m | | | \$m | \$m | | |
| Sales | 4,436 | 4,312 | +3 | -4 | 9,171 | 8,658 | +6 | - |
| Operating Profit | 889 | 1,064 | -16 | -18 | 2,161 | 2,361 | -8 | -10 |
| Profit before Tax | 921 | 1,065 | -14 | -17 | 2,214 | 2,383 | -7 | -9 |
| Earnings per Share | \$ 0.39 | \$ 0.45 | -13 | -16 | \$ 0.93 | \$ 1.00 | -6 | -8 |

All narrative in this section refers to growth rates at constant exchange rates (CER)

- Sales for the first half year were unchanged in CER terms despite the loss of \$1.2 billion in US sales of Prilosec, Zestril and Nolvadex.
- Operating profit for the first half declined by 10 percent, chiefly on lower other operating income this year (\$62 million) in comparison to last year (\$211 million), which included a disposal gain.
- Sales for key growth and launch products increased by 48 percent to \$3.7 billion in the first half.
- Second quarter sales were down 4 percent as a result of the anticipated wholesaler destocking in the US market. Sales outside the US increased 4 percent.
- Operating profit in the second quarter was down 18 percent, as the anticipated destocking was accompanied by modest increases (up 3 percent CER) in R&D and SG&A expense.
- Nexium sales in the first half increased by 76 percent to \$1,466 million. Sales in the last 12 months exceeded \$2.6 billion.
- Crestor sales were \$12 million as the product continues to perform well in its first launch markets. On 9 July an Advisory Committee to the US Food and Drug Administration voted unanimously to recommend approval for Crestor.
- Sales of Iressa were \$66 million in the first half year, including \$18 million in the US since its launch in mid-May.
- The Board has recommended an increase in the interim dividend to \$0.255.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Sir Tom McKillop, Chief Executive, said: "The successful transformation of our product range is shown by the replacement of \$1.2 billion US sales of Prilosec , Zestril and Nolvadex lost to generics by new and high growth products, leaving sales unchanged for the first half. As a result of this strong sales performance and prospects for the rest of the year we have raised our earnings target for the year to the range of \$1.65 to \$1.75 per share. We have also increased the interim dividend by 10 percent to \$0.255.

London, 24 July 2003

| | | |
|-----------------------------|-----------------------------------|-------------------------------|
| Media Enquiries: | Steve Brown/Emily Denney (London) | (020) 7304 5033/5034 |
| | Staffan Ternby (Södertälje) | (8) 553 26107 |
| | Rachel Bloom (Wilmington) | (302) 886 7858 |
| Analyst/Investor Enquiries: | Mina Blair-Robinson (London) | (020) 7304 5084 |
| | Jonathan Hunt (London) | (020) 7304 5087 |
| | Staffan Ternby (Södertälje) | (8) 553 26107 |
| | Ed Seage/Jörgen Winroth (USA) | (302) 886 4065/(212) 581 8720 |

AstraZeneca PLC

Business Highlights *All narrative in this section refers to growth rates at constant exchange rates (CER) unless otherwise indicated.*

First Half

First half sales were unchanged from the prior year in CER terms. The strengthening of exchange rates versus the US dollar lifted the actual sales growth rate to 6 percent. Operating profit was down 10 percent, chiefly on significantly lower other operating income in comparison to last year, which included a disposal gain. Costs were well managed as SG&A and R&D costs grew by 4 percent in CER terms. The currency benefit on operating profit was 2 percentage points positive. Earnings per share declined by 8 percent to \$0.93. In view of the increased expectations for the year and the progress of the portfolio transformation, the Board has recommended an increased first interim dividend of \$0.255 (15.9 pence; SEK 2.07) to be paid on 6 October 2003.

Sales for the first half were up 5 percent in markets outside the US, and were down by 4 percent in the US market. The portfolio transformation is progressing well. Global sales of the cohort of ten recently launched and growth products increased by 48 percent to \$3.7 billion, and now comprise 40 percent of sales. This strong growth offset the loss of \$1.2 billion US sales of Prilosec , Zestril and Nolvadex , leaving total first half sales unchanged compared to 2002.

Nexium sales increased by 76 percent in the first half, with strong growth in the US (up 74 percent) and in the rest of the world (up 83 percent). During the second quarter, Nexium share of new prescriptions in the US PPI market surpassed those of Prilosec and generic omeprazole combined. Nexium now ranks second in new prescriptions share of the overall US PPI market, and first in new prescriptions by gastroenterologists.

Symbicort sales were \$249 million in the first half (up 79 percent) on market share gains in the rapidly growing market for fixed combination asthma treatments.

Sales for Iressa reached \$66 million in the first half, including \$18 million in sales in the US since launch in mid-May. Through the end of June nearly 5,000 retail prescriptions have been dispensed for Iressa in the US and, including patients still in the expanded access programme, it is estimated that as many as 10,000 patients may be currently taking Iressa in this market.

Crestor continues to perform well in its first launch markets. Sales were \$12 million in the first half. Crestor share of the dynamic segment of the statin market (defined as new and switch patients but excluding from the data pool patients who are simply continuing their existing treatment) is around 30 percent in Canada (private payer segment only) and in the Netherlands. On 9 July the Endocrinology and Metabolic Advisory Committee to the US Food and Drug Administration voted unanimously to recommend approval for Crestor .

Second Quarter

Sales in the second quarter were down 4 percent in CER terms. The weaker US dollar lifted the reported actual sales growth to 3 percent. Operating profit was down 18 percent as costs grew against a sales decline. R&D and SG&A costs continue to be tightly managed, growing by 3 percent in CER terms. The currency effect on operating profit was 2 percentage points positive. Earnings per share in the second quarter were 16 percent lower, at \$0.39.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Sales outside the US increased by 4 percent in the quarter, as sales growth from Nexium , Symbicort and Oncology products more than offset declines in Losec and Zestril .

US sales were down 11 percent as a result of wholesaler destocking and as generic erosion continued on Prilosec (down 52 percent), Nolvadex (down 94 percent) and Zestril (down 86 percent). US sales excluding these three products grew by 23 percent (or by an estimated 35 percent on an underlying demand basis, adjusted for the net destocking effect).

As expected, wholesaler stocks declined from the levels seen in the first quarter. Estimated inventory levels at the end of the second quarter are now at or below normal for Nexium and Seroquel and are trending down for Atacand . Wholesaler purchasing in excess of underlying demand continued for Toprol-XL in the second quarter. Across the entire product range, the company estimates the value of inventory in the distribution channels has been reduced to around \$200 million above normal (half the level at the end of the first quarter), the majority of which is Toprol-XL .

2

AstraZeneca PLC

Future Prospects All narrative in this section refers to growth rates at constant exchange rates (CER) unless otherwise indicated.

Based on the strong performance to date, prospects for the second half, and assuming current exchange rates hold for the remainder of the year, the company has increased its expectations for earnings per share for the full year to the range of \$1.65 to \$1.75 per share.

Disclosure Notice: The preceding forward looking statements relating to expectations for earnings and business prospects for AstraZeneca PLC are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the forward looking statements. These include, but are not limited to: the rate of growth in sales of generic omeprazole in the USA, the successful registration and launch of new products (in particular Crestor , Iressa , and Exanta), continued growth of currently marketed products, the growth in costs and expenses, interest rate movements, exchange rate fluctuations, and changes in the tax rate. For further details on these and other risks and uncertainties, see AstraZeneca PLC s Securities and Exchange Commission filings, including the 2002 Annual Report on Form 20-F.

3

AstraZeneca PLC

Sales

All narrative in this section refers to growth rates at constant exchange rates (CER) unless otherwise indicated.

Gastrointestinal

| | Second Quarter | | CER % | Half Year | | CER % |
|--------|-----------------|-------|-------|-----------|-------|-------|
| | 2003 | 2002 | | 2003 | 2002 | |
| | Losec /Prilosec | 742 | 1,116 | -39 | 1,434 | 2,308 |
| Nexium | 631 | 464 | +31 | 1,466 | 811 | +76 |
| Total | 1,390 | 1,597 | -18 | 2,935 | 3,149 | -11 |

- Sales of Nexium in the second quarter grew by 50 percent in markets outside the US. Total prescriptions in the US for the second quarter grew by 50 percent , but wholesaler destocking resulted in a sales increase of 25 percent. The company believes that US wholesaler inventories for Nexium are now at or even somewhat below normal at the end of the quarter.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

- Sales of Nexium in the first half were up 74 percent in the US, and by 83 percent in the rest of the world. Global sales of Nexium in the last 12 months exceeded \$2.6 billion.
- Nexium continues to build upon its market leading share of new prescriptions by GI specialists in the US, and in the overall market, Nexium prescriptions have now overtaken those of Prilosec and omeprazole combined, to become the number two PPI in the US market.
- US sales of Prilosec were down by 52 percent in the second quarter and by 56 percent in the half year. Total prescriptions in the US were down by 65 percent through June. Prilosec share of total omeprazole prescriptions in the US was 35 percent in June.
- Sales of Losec in markets outside the US were down by 18 percent in the quarter, and by 20 percent in the first half. Good growth is still being achieved in Japan, with sales up 48 percent in the first half.

Cardiovascular

| | Second Quarter | | CER % | Half Year | | CER % |
|--------------|---------------------|------------|-----------|--------------|--------------|----------|
| | 2003 | 2002 | | 2003 | 2002 | |
| | Seloken / Toprol-XL | 380 | | 206 | +79 | |
| Atacand | 152 | 129 | +6 | 358 | 278 | +20 |
| Plendil | 129 | 97 | +26 | 239 | 203 | +12 |
| Zestril | 118 | 269 | -61 | 226 | 546 | -63 |
| Crestor | 9 | - | n/m | 12 | - | n/m |
| Total | 967 | 889 | +1 | 1,936 | 1,835 | - |

- Toprol-XL continues its strong growth in the US. Market share of total beta blocker prescriptions reached 25.1 percent in June, and prescriptions increased by 29 percent through June. US sales in the second quarter (up 112 percent) once again exceeded underlying demand. As a result, the company estimates channel inventories are more than \$150 million above normal levels at the end of the quarter.
outside the US increased by 13 percent in the second quarter and by 12 percent in the first half.
- Sales of Seloken /Toprol-XL percent in the first half.
- Total prescriptions for Atacand products in the US were up 14 percent through June, and first half sales were up 20 percent. US sales were down 19 percent in the second quarter on wholesaler destocking of inventories which, although declining, remain higher than normal at the end of the period.
- Sales of Atacand outside the US increased by 17 percent in the quarter and by 19 percent in the first half.

- Sales of Crestor totalled \$12 million in the first half, \$9 million of which came in the second quarter. The performance of Crestor in the three largest markets where it has launched to date Canada, the Netherlands, and the UK continues to meet the company's expectations. From an analysis of the dynamic segment of the statin market (which excludes patients from the data pool who are simply continuing their current medication) the company estimates that in the Canadian private payer market Crestor has around a 30 percent share after 21 weeks, and a similar share in the Netherlands after 19 weeks.
- Crestor was launched in Sweden and four other countries in the second quarter. The company is planning for another six launches before the end of 2003, including the US. Approval in Japan is now expected to be in the first half of 2004.
- On 9 July the Endocrinology and Metabolic Advisory Committee to the US Food and Drug Administration voted unanimously to recommend approval for Crestor as an adjunct to diet for the treatment of various lipid disorders.

Respiratory

| | Second Quarter | | CER % | Half Year | | CER % |
|-----------|----------------|------|-------|-----------|------|-------|
| | 2003 | 2002 | | 2003 | 2002 | |
| Symbicort | 127 | 68 | +61 | 249 | 122 | +79 |
| Pulmicort | 239 | 199 | +13 | 490 | 426 | +9 |
| Rhinocort | 96 | 81 | +17 | 186 | 144 | +26 |
| Accolate | 25 | 33 | -27 | 56 | 65 | -16 |
| Oxis | 29 | 30 | -16 | 60 | 61 | -13 |
| Total | 552 | 448 | +13 | 1,115 | 890 | +16 |

- Symbicort sales were up 61 percent in the second quarter and by 79 percent in the first half. The combination market continues to grow strongly and Symbicort is gaining market share. Market share across Europe is now over 25 percent; Symbicort in Sweden is over 50 percent of the fixed combination market, in Germany it is 33 percent, and in France, it has achieved 30 percent of the market according to the most recent monthly data. The regulatory submission in the US for Symbicort is now scheduled for 2005.
- Pulmicort sales in the US were up 51 percent in the second quarter and by 37 percent in the first half, chiefly on strong prescription growth for Pulmicort Respules (up 34 percent through June) coupled with wholesaler stocking on both Pulmicort Respules and Pulmicort Turbuhaler .
- Sales of Rhinocort reflect growth in the US market (up 39 percent in the first half), where increasing sales of Rhinocort Aqua have more than offset the sales lost from the discontinuation of Rhinocort Nasal Inhaler (due to the phase-out of CFC containing products). Market share and total prescriptions for Rhinocort Aqua have grown on a year-to-date basis, as have wholesaler inventories.

5

AstraZeneca PLC

Oncology

| | Second Quarter | | CER % | Half Year | | CER % |
|----------|----------------|------|-------|-----------|-------|-------|
| | 2003 | 2002 | | 2003 | 2002 | |
| Casodex | 228 | 148 | +41 | 417 | 271 | +43 |
| Zoladex | 213 | 195 | - | 406 | 382 | -1 |
| Arimidex | 143 | 79 | +70 | 236 | 144 | +54 |
| Iressa | 47 | - | n/m | 66 | - | n/m |
| Faslodex | 15 | 8 | +88 | 37 | 8 | n/m |
| Nolvadex | 39 | 117 | -70 | 100 | 257 | -63 |
| Total | 690 | 553 | +15 | 1,271 | 1,073 | +10 |

- Casodex sales in markets outside the US were up 19 percent in the quarter, and by 22 percent in the first half. The second quarter sales growth rate in the US (up 118 percent) reflects wholesaler stocking in the current quarter coupled with destocking in the same period last year.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

- Sales for Arimidex outside the US increased by 50 percent in the quarter and by 46 percent at the half year. The indication for adjuvant treatment for early breast cancer is now approved in 25 countries. Arimidex share of the global market for aromatase inhibitors has increased by 15 percentage points since the clinical data supporting its use for early breast cancer were first presented in December 2001.
- Total prescriptions for Arimidex in the US are up 54 percent through June. Sales were up 66 percent in the first half, but were up 94 percent in the second quarter, indicating some wholesaler stockbuilding in the quarter.
- In May it was announced that clinical trials in the US and in Europe will evaluate the efficacy and safety of Arimidex in patients with very early breast cancer and in women at high risk of developing the disease.
- Sales of Iressa reached \$66 million in the first half, including \$18 million in the US since launch in mid-May. Through June nearly 5,000 retail prescriptions have been dispensed for Iressa in the US. Sales in Japan in the second quarter returned to a more normal trend line from that seen in the first quarter.
- Faslodex sales increased to \$37 million in the first half, indicating that Faslodex is a welcome addition to treatment options for the management of advanced breast cancer.
- The global sales decline in Nolvadex reflects the entry of multiple generic tamoxifen products in the US market since the end of February.

CNS

| | Second Quarter | | CER % | Half Year | | CER % |
|--------------|----------------|------------|-----------|------------|------------|------------|
| | 2003 | 2002 | | 2003 | 2002 | |
| | Seroquel | 270 | 263 | -1 | 714 | 592 |
| Zomig | 54 | 74 | -35 | 162 | 166 | -8 |
| Total | 331 | 345 | -9 | 891 | 773 | +11 |

- Total prescriptions for Seroquel in the US continue to grow strongly, up 35 percent through June. Market share in June was 19.6 percent, up 2 points this year. Seroquel is the only product among the top three in the atypical antipsychotic class to gain market share this year.
- In contrast to the prescription trend, Seroquel sales in the US have been distorted by wholesaler stocking patterns. Sales in the second quarter were down 11 percent as the above normal wholesaler inventories carried from the first quarter were unwound. First half sales were up 10 percent, with inventories at the end of the period back to normal levels.

6

AstraZeneca PLC

- Seroquel sales outside the US increased by 38 percent in the second quarter and by 56 percent in the first half.
- Sales of Zomig outside the US increased by 6 percent in both the second quarter and the first half. In the US, second quarter sales were down 76 percent as wholesalers destocked following the April price changes.

Pain, Infection and Other Pharma

| | Second Quarter | | CER % | Half Year | | CER % |
|----------|----------------|------|-------|-----------|------|-------|
| | 2003 | 2002 | | 2003 | 2002 | |
| | Merrem | 80 | 74 | +5 | 154 | 141 |
| Diprivan | 98 | 111 | -17 | 234 | 222 | - |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | |
|-----------|-----|-----|-----|-----|-----|-----|
| Xylocaine | 50 | 45 | +9 | 88 | 85 | +2 |
| Marcaine | 23 | 18 | +22 | 42 | 35 | +14 |
| Total | 369 | 357 | -2 | 746 | 699 | +2 |

- Merrem sales growth of 8 percent in the first half resulted from growth in non-US markets (up 16 percent) more than offsetting a decline in US sales (down 22 percent) due to constrained supply.
- Sales of Diprivan were unchanged in the first half, as US stockbuilding in the first quarter of this year was followed by destocking in the second quarter.

Geographic Sales

| | Second Quarter | | CER % | Half Year | | CER % |
|--------|----------------|-------|-------|-----------|-------|-------|
| | 2003 | 2002 | | 2003 | 2002 | |
| USA | 1,962 | 2,214 | -11 | 4,432 | 4,597 | -4 |
| Europe | 1,646 | 1,401 | -2 | 3,201 | 2,788 | -1 |
| Japan | 293 | 240 | +11 | 536 | 412 | +20 |
| RoW | 535 | 457 | +17 | 1,002 | 861 | +18 |

- Second quarter sales in the US were down 11 percent and were affected, as expected, by wholesaler destocking of the above normal inventories present at the end of the first quarter. Generic competition for Prilosec, Zestril, and Nolvadex reduced sales of these three products by \$ 1.2 billion in the first half, yet total US sales were off just 4 percent.
- Sales in Europe were down 2 percent in the quarter and by 1 percent the first half. Growth in France and Spain was offset by sales declines in the UK and pricing pressures in Italy and Germany. Notable product growth was achieved for Nexium, Symbicort, Seroquel, and Casodex.
- Sales growth in Japan in the first half (up 20 percent) was driven by Iressa, Seroquel, Losec, and Casodex.

AstraZeneca PLC

Operating Review

Half Year

Reported sales were up 6 percent (unchanged CER) and operating profits down 8 percent (CER down 10 percent). The weaker US dollar increased sales growth by 6 percentage points but also increased costs so that the effect at the profit level was reduced to 2 points. Gross margin increased by 0.5 points due to favourable mix, including lower proportional payments to Merck. Operating margins declined by 3.7 points to 23.6 percent. R&D and SG&A continue to be tightly managed, growing by 4 percent in CER terms. Other operating income is significantly lower in comparison with last year, which included a disposal gain and accounts for around 1.6 points of the margin decline.

Second Quarter

Reported sales grew by 3 percent, operating profits fell by 16 percent. At constant exchange rates, sales fell by 4 percent and operating profit by 18 percent. Operating margin at 20.0 percent fell by 4.7 percentage points as a result of declining sales while costs increased. Currency also depressed margins. R&D and SG&A costs remained well controlled in the quarter increasing by only 3 percent in CER terms. Also, in the quarter, the disposal of Marlow Foods was completed and a small gain was included in other income.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Currency for the year is expected to have a small positive effect on earnings per share (around 4 cents) as the relative strength of the Euro has a positive effect on sales, outweighing the negative effect on costs as a result of the stronger sterling and Swedish Krona.

Wholesaler Stocking

Sales in the first quarter's results were increased by speculative wholesaler purchases made ahead of anticipated price increases. At the end of the first quarter it was estimated that wholesaler inventories were approximately \$400 million above normal. As expected, during the second quarter, inventory levels reduced and at the end of June it was estimated that wholesaler inventories had fallen to around \$200 million above normal, a significant part of which was Toprol-XL with most other major products affected including Nexium and Seroquel having returned to normal or below normal levels.

Interest and Dividend Income

Net interest and dividend income for the first half of 2003 was \$53 million, \$32 million in the second quarter, with higher overall cash balances compensating for lower yields on investments together with a reduction in exchange losses (particularly in the second quarter) compared with the same periods last year.

Taxation

The effective tax rate for the second quarter and half year was 27.5 percent compared with 27.0 percent for the comparative periods in 2002.

Cash Flow

Cash generated from operating activities before exceptional items in the first half of the year fell to \$2,473 million from \$3,149 million in the comparative period, a decline caused by a combination of lower operating profits, inventory increase and the timing of creditor settlements. Cash expenditure on exceptional items was \$381 million, compared to \$55 million in 2002 the Zoladex settlement in the second quarter was the major element. Tax paid in the first six months was \$762 million, \$347 million higher than the same period in 2002 due to earlier payment of US taxes. Net capital expenditure was broadly comparable with the comparative period, totalling \$673 million in the six months. The cash inflow of \$80 million in respect of acquisitions and disposals represents the disposal of Marlow Foods in the second quarter. Share repurchases totalled \$311 million and in the second quarter indebtedness of \$319 million was repaid. Net cash funds fell by \$235 million from the beginning of the year to stand at \$3,609 million at 30 June 2003.

8

AstraZeneca PLC

Dividends

A first interim dividend of \$0.255 (15.9 pence, SEK 2.07) will be paid on 6 October 2003 to all shareholders on the register on 22 August 2003.

Share Repurchase Programme

During the second quarter 4.6 million ordinary shares were repurchased for cancellation at a cost of \$182 million bringing the total repurchases for the first half of the year to 8.6 million shares at a total cost of \$311 million. Since the start of this programme 74.2 million shares have been repurchased at a total cost of \$3,116 million. The total number of shares in issue (as at 30 June 2003) is 1,710 million. Approximately \$900 million remains available under the previously announced share repurchase programme.

Upcoming Milestones and Key Events

| | |
|------------|---|
| 2 October | Annual Business Review, Wilmington, USA |
| 23 October | Announcement of third quarter results |

Sir Tom McKillop
Chief Executive

9

Item 6**Consolidated Profit & Loss Account**

| For the six months ended 30 June | 2003 | 2002 |
|--|--------------|--------------|
| | \$m | \$m |
| Sales | 9,171 | 8,658 |
| Cost of sales | (2,237) | (2,154) |
| Distribution costs | (75) | (65) |
| Research and development | (1,597) | (1,420) |
| Selling, general and administrative expenses | (3,163) | (2,869) |
| Other operating income | 62 | 211 |
| Operating profit | 2,161 | 2,361 |
| Net interest and dividend income | 53 | 22 |
| Profit on ordinary activities before taxation | 2,214 | 2,383 |
| Taxation | (609) | (644) |
| Profit on ordinary activities after taxation | 1,605 | 1,739 |
| Attributable to minorities | (7) | (6) |
| Net profit for the period | 1,598 | 1,733 |
| Dividends to shareholders | (436) | (398) |
| Retained profit for the period | 1,162 | 1,335 |
| Earnings per Ordinary Share | \$ 0.93 | \$ 1.00 |
| Diluted earnings per Ordinary Share | \$ 0.93 | \$ 1.00 |
| Weighted average number of Ordinary Shares in issue (millions) | 1,714 | 1,741 |
| Diluted average number of Ordinary Shares in issue (millions) | 1,716 | 1,743 |

Consolidated Profit & Loss Account

| For the quarter ended 30 June | 2003 \$m | 2002 \$m |
|--|---------------------------|---------------------------|
| Sales | 4,436 | 4,312 |
| Cost of sales | (1,102) | (1,060) |
| Distribution costs | (40) | (35) |
| Research and development | (815) | (723) |
| Selling, general and administrative expenses | (1,637) | (1,485) |
| Other operating income | 47 | 55 |
| Operating profit | 889 | 1,064 |
| Net interest and dividend income | 32 | 1 |
| Profit on ordinary activities before taxation | 921 | 1,065 |
| Taxation | (253) | (288) |
| Profit on ordinary activities after taxation | 668 | 777 |
| Attributable to minorities | (2) | (2) |
| Net profit for the period | 666 | 775 |
| Dividends to shareholders | (436) | (398) |
| Retained profit for the period | 230 | 377 |
| Earnings per Ordinary Share | \$ 0.39 | \$ 0.45 |
| Diluted earnings per Ordinary Share | \$ 0.39 | \$ 0.45 |
| Weighted average number of Ordinary Shares in issue (millions) | 1,712 | 1,736 |
| Diluted average number of Ordinary Shares in issue (millions) | 1,714 | 1,738 |

11

Consolidated Balance Sheet

| | 30 June 2003 \$m | 30 June 2002 \$m |
|---------------------|---|---|
| Fixed assets | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | |
|--|---------|---------|
| Tangible fixed assets | 7,005 | 6,079 |
| Goodwill and intangible assets | 2,863 | 2,748 |
| Fixed asset investments | 47 | 22 |
| | <hr/> | <hr/> |
| | 9,915 | 8,849 |
| Current assets | | |
| Stocks | 2,765 | 2,460 |
| Debtors | 5,479 | 4,648 |
| Cash and short-term investments | 3,987 | 4,247 |
| | <hr/> | <hr/> |
| | 12,231 | 11,355 |
| | <hr/> | <hr/> |
| Total assets | 22,146 | 20,204 |
| | <hr/> | <hr/> |
| Creditors due within one year | | |
| Short-term borrowings and current instalments of loans | (55) | (476) |
| Other creditors | (7,047) | (6,646) |
| | <hr/> | <hr/> |
| | (7,102) | (7,122) |
| | <hr/> | <hr/> |
| Net current assets | 5,129 | 4,233 |
| | <hr/> | <hr/> |
| Total assets less current liabilities | 15,044 | 13,082 |
| | <hr/> | <hr/> |
| Creditors due after more than one year | | |
| Loans | (323) | (337) |
| Other creditors | (42) | (153) |
| Provisions for liabilities and charges | (1,922) | (1,547) |
| | <hr/> | <hr/> |
| | (2,287) | (2,037) |
| | <hr/> | <hr/> |
| Net assets | 12,757 | 11,045 |
| | <hr/> | <hr/> |
| Capital and reserves | | |
| Shareholders' funds - equity interests | 12,696 | 10,994 |
| Minority equity interests | 61 | 51 |
| | <hr/> | <hr/> |
| Shareholders' funds and minority interests | 12,757 | 11,045 |
| | <hr/> | <hr/> |

Statement of Total Recognised Gains and Losses

| | 2003 | 2002 |
|---|-------------|-------------|
| | \$m | \$m |
| For the six months ended 30 June | | |
| | <hr/> | <hr/> |
| Net profit for the period | 1,598 | 1,733 |
| Exchange adjustments on net assets | 647 | 797 |
| Translation differences on foreign currency borrowings | - | (5) |
| Tax on translation differences on foreign currency borrowings | - | - |
| Other movements | - | 3 |
| | <hr/> | <hr/> |

| | | |
|---|-------|-------|
| Total recognised gains and losses relating to the period | 2,245 | 2,528 |
|---|-------|-------|

12

Consolidated Cash Flow Statement

| For the six months ended 30 June | 2003 | 2002 |
|--|--------------|--------------|
| | \$m | \$m |
| Cash flow from operating activities | | |
| Operating profit | 2,161 | 2,361 |
| Depreciation | 417 | 328 |
| Amortisation | 141 | 131 |
| (Increase)/decrease in working capital | (346) | 251 |
| Other non-cash movements | 100 | 78 |
| Net cash inflow from operating activities before exceptional items | 2,473 | 3,149 |
| Outflow related to exceptional items | (381) | (55) |
| Net cash inflow from operating activities | 2,092 | 3,094 |
| Returns on investments and servicing of finance | 33 | 3 |
| Tax paid | (762) | (415) |
| Capital expenditure and financial investment | | |
| Net cash expenditure on fixed assets | (673) | (632) |
| Cash expenditure on fixed asset investments | - | (1) |
| | (673) | (633) |
| Acquisitions and disposals | 80 | - |
| Equity dividends paid to Shareholders | (770) | (820) |
| Net cash inflow before management of liquid resources and financing | - | 1,229 |
| Management of liquid resources | | |
| Movement in short-term investments and fixed deposits (net) | 487 | (428) |
| Financing | (604) | (815) |

| | | |
|---|-------|-------|
| Decrease in cash in the period | (117) | (14) |
| <hr/> | | |
| Net cash funds | | |
| <hr/> | | |
| Net cash inflow before management of liquid resources and financing | - | 1,229 |
| AstraZeneca PLC Ordinary Shares | | |
| Issued for cash | 26 | 26 |
| Repurchased for cash | (311) | (748) |
| <hr/> | | |
| (Outflow)/inflow of net cash funds in the period | (285) | 507 |
| <hr/> | | |

Independent Review Report by KPMG Audit Plc to AstraZeneca PLC

Introduction

We have been engaged by the Company to review the financial information for the six month period ended 30 June 2003 set out on pages 10 and 12 to 16 and we have read the other information contained in the interim report and considered whether it contains any apparent misstatements or material inconsistencies with the financial information.

This report is made solely to the Company in accordance with the terms of our engagement to assist the Company in meeting the requirements of the Listing Rules of the Financial Services Authority. Our review has been undertaken so that we might state to the Company those matters we are required to state to it in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company for our review work, for this report, or for the conclusions we have reached.

Directors' responsibilities

The interim report, including the financial information contained therein, is the responsibility of, and has been approved by, the Directors. The Directors are responsible for preparing the interim report in accordance with the Listing Rules which require that the accounting policies and presentation applied to the interim figures should be consistent with those applied in preparing the preceding annual accounts except where they are to be changed in the next annual accounts in which case any changes, and the reasons for them, are disclosed.

Review work performed

We conducted our review in accordance with guidance contained in Bulletin 1999/4: Review of Interim Financial Information issued by the Auditing Practices Board for use in the United Kingdom. A review consists principally of making enquiries of group management and applying analytical procedures to the financial information and underlying financial data and, based thereon, assessing whether the accounting policies and presentation have been consistently applied unless otherwise disclosed. A review is substantially less in scope than an audit performed in accordance with Auditing Standards and therefore provides a lower level of assurance than an audit. Accordingly, we do not express an audit opinion on the financial information.

Review conclusion

On the basis of our review we are not aware of any material modifications that should be made to the financial information as presented for the six months ended 30 June 2003.

KPMG Audit Plc
Chartered Accountants
8 Salisbury Square
London

24 July 2003

Notes to the Interim Financial Statements

1 BASIS OF PREPARATION AND ACCOUNTING POLICIES

The unaudited financial statements for the six months ended 30 June 2003 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 2002 Annual Report and Form 20-F.

The financial statements are unaudited but have been reviewed by the auditors and their report is set out above. These interim financial statements do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2002 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

As part of AstraZeneca's objective to align with best accounting practice, cash discounts arising from prompt payments of invoices were reclassified from cost of sales to sales for the year ended 31 December 2002. Comparatives were reclassified and additional detail at product and territorial level are available on the AstraZeneca website. Both sales and cost of sales were reduced by \$145m in the first half 2002. Neither profits nor net assets were affected.

2 JOINT VENTURES AND ASSOCIATES

The group's share of joint ventures' sales for the half year to 30 June 2003 amounted to \$174m and \$173m for the comparative period. Share of joint ventures' operating profits for the half year to 30 June 2003, and for the comparative period, were \$nil.

14

3 RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS

| For the six months ended 30 June | 2003 \$m | 2002 \$m |
|---|--------------------|--------------------|
| Shareholders' funds at beginning of period | 11,172 | 9,586 |
| Net profit for the period | 1,598 | 1,733 |
| Dividends to Shareholders | (436) | (398) |
| | 1,162 | 1,335 |
| Issue of AstraZeneca PLC Ordinary Shares | 26 | 26 |
| Repurchase of AstraZeneca PLC Ordinary Shares | (311) | (748) |
| Foreign currency adjustment | 647 | 792 |
| Other movements | - | 3 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | |
|--------------------------------------|--------|--------|
| Net addition to Shareholders' funds | 1,524 | 1,408 |
| Shareholders' funds at end of period | 12,696 | 10,994 |
| 4 NET CASH FUNDS | | |

The table below provides an analysis of net cash funds and a reconciliation of net cash flow to the movement in net cash funds.

| | At 31 Dec 2002 \$m | Cash flow \$m | Other Non-cash \$m | Exchange Movements \$m | At 30 June 2003 \$m |
|--|--------------------------|---------------------|--------------------------|------------------------------|---------------------------|
| Loans due after 1 year | (328) | - | 5 | - | (323) |
| Current instalments of loans | (314) | 319 | (5) | - | - |
| Total loans | (642) | 319 | - | - | (323) |
| Short-term investments | 3,962 | (487) | - | 28 | 3,503 |
| Cash | 726 | (264) | - | 22 | 484 |
| Overdrafts | (202) | 147 | - | - | (55) |
| | 4,486 | (604) | - | 50 | 3,932 |
| Net cash funds | 3,844 | (285) | - | 50 | 3,609 |
| Issue of AstraZeneca PLC Ordinary Shares | | (26) | | | |
| Repurchase of AstraZeneca PLC Ordinary Shares | | 311 | | | |
| Net cash inflow before management of liquid resources and financing | | - | | | |

5 LEGAL PROCEEDINGS

The Company announced on 20 June 2003 a settlement of the US Department of Justice investigation into the US sales and marketing practices for Zoladex (goserelin acetate implant). Under the terms of the settlement, AstraZeneca Pharmaceuticals LP admitted to violating the Prescription Drug Marketing Act by providing free samples of Zoladex to physicians during the period 1993 through 1996, with the understanding that these physicians would bill Medicare for reimbursement. AstraZeneca also settled, without admitting liability, civil claims involving allegations that the Company provided inducements to physicians to purchase Zoladex and for improperly setting and reporting its price. The total payment associated with the settlement is \$355 million, with a portion of the settlement placed in escrow to fund anticipated settlements with the individual states. The settlement also provides for a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) for the Department of Health and Human Services, under which AstraZeneca Pharmaceuticals LP is required, among other obligations, to keep in place its current Compliance Program and provide periodic reports to the OIG on the status of compliance activities.

6 HALF YEAR TERRITORIAL SALES ANALYSIS

| | 1 st Half 2003 \$m | 1 st Half 2002 \$m | % Growth | |
|---------------|-------------------------------------|-------------------------------------|----------|----------------------|
| | | | Actual | Constant Currency |
| US | 4,432 | 4,597 | (4) | (4) |
| Canada | 330 | 273 | 21 | 16 |
| North America | 4,762 | 4,870 | (2) | (2) |
| France | 688 | 533 | 29 | 9 |
| UK | 274 | 325 | (16) | (24) |
| Germany | 390 | 329 | 19 | 1 |
| Italy | 450 | 379 | 19 | 1 |
| Sweden | 152 | 138 | 10 | (7) |
| Europe others | 1,247 | 1,084 | 15 | (1) |
| Total Europe | 3,201 | 2,788 | 15 | (1) |
| Japan | 536 | 412 | 30 | 20 |
| Rest of World | 672 | 588 | 14 | 19 |
| Total | 9,171 | 8,658 | 6 | - |

7 SECOND QUARTER TERRITORIAL SALES ANALYSIS

| | 2 nd Half 2003 \$m | 2 nd Half 2002 \$m | % Growth | |
|---------------|-------------------------------------|-------------------------------------|----------|----------------------|
| | | | Actual | Constant Currency |
| US | 1,962 | 2,214 | (11) | (11) |
| Canada | 174 | 144 | 21 | 13 |
| North America | 2,136 | 2,358 | (9) | (10) |
| France | 359 | 270 | 33 | 10 |
| UK | 130 | 147 | (12) | (21) |
| Germany | 207 | 165 | 25 | 4 |
| Italy | 242 | 207 | 17 | (3) |
| Sweden | 73 | 74 | (1) | (16) |
| Europe others | 635 | 538 | 18 | - |
| Total Europe | 1,646 | 1,401 | 17 | (2) |
| Japan | 293 | 240 | 22 | 11 |
| Rest of World | 361 | 313 | 15 | 19 |

| | | | | |
|-------|-------|-------|---|-----|
| Total | 4,436 | 4,312 | 3 | (4) |
|-------|-------|-------|---|-----|

16

8 HALF YEAR PRODUCT SALES ANALYSIS

| | World | | | | US | |
|------------------------|----------------------------|----------------------------|-----------------------|-------------------------------------|----------------------------|-----------------------|
| | 1st Half 2003 \$m | 1st Half 2002 \$m | Actual Growth % | Constant Currency Growth % | 1st Half 2003 \$m | Actual Growth % |
| Gastrointestinal: | | | | | | |
| Losec | 1,434 | 2,308 | (38) | (42) | 607 | (56) |
| Nexium | 1,466 | 811 | 81 | 76 | 1,106 | 74 |
| Others | 35 | 30 | 17 | 7 | 11 | 22 |
| Total Gastrointestinal | 2,935 | 3,149 | (7) | (11) | 1,724 | (15) |
| Cardiovascular: | | | | | | |
| Zestril | 226 | 546 | (59) | (63) | 43 | (87) |
| Seloken | 748 | 437 | 71 | 67 | 576 | 93 |
| Atacand | 358 | 278 | 29 | 20 | 137 | 20 |
| Plendil | 239 | 203 | 18 | 12 | 89 | 24 |
| Tenormin | 165 | 190 | (13) | (18) | 13 | (65) |
| Crestor | 12 | - | n/m | n/m | - | n/m |
| Others | 188 | 181 | 4 | (8) | 9 | (18) |
| Total Cardiovascular | 1,936 | 1,835 | 6 | - | 867 | (1) |
| Respiratory: | | | | | | |
| Pulmicort | 490 | 426 | 15 | 9 | 261 | 37 |
| Rhinocort | 186 | 144 | 29 | 26 | 136 | 39 |
| Symbicort | 249 | 122 | 104 | 79 | - | - |
| Accolate | 56 | 65 | (14) | (16) | 38 | (16) |
| Oxis | 60 | 61 | (2) | (13) | - | - |
| Others | 74 | 72 | 3 | (8) | - | - |
| Total Respiratory | 1,115 | 890 | 25 | 16 | 435 | 31 |
| Oncology: | | | | | | |
| Zoladex | 406 | 382 | 6 | (1) | 84 | (17) |
| Casodex | 417 | 271 | 54 | 43 | 132 | 110 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | |
|---|--------------|--------------|-----------|-----------|--------------|------------|
| Nolvadex | 100 | 257 | (61) | (63) | 36 | (81) |
| Arimidex | 236 | 144 | 64 | 54 | 101 | 66 |
| Iressa | 66 | - | n/m | n/m | 18 | n/m |
| Faslodex | 37 | 8 | n/m | n/m | 37 | n/m |
| Others | 9 | 11 | (18) | (27) | - | - |
| Total Oncology | 1,271 | 1,073 | 18 | 10 | 408 | (3) |
| CNS: | | | | | | |
| Seroquel | 714 | 592 | 21 | 18 | 545 | 10 |
| Zomig | 162 | 166 | (2) | (8) | 78 | (19) |
| Others | 15 | 15 | - | (13) | 2 | (33) |
| Total CNS | 891 | 773 | 15 | 11 | 625 | 5 |
| Pain, Infection and Other Pharma: | | | | | | |
| Diprivan | 234 | 222 | 5 | - | 123 | 13 |
| Merrem | 154 | 141 | 9 | 8 | 25 | (22) |
| Local anaesthetics | 223 | 156 | 43 | 34 | 51 | 55 |
| Other Pharma Products | 135 | 180 | (25) | (31) | 31 | (44) |
| Total Pain, Infection and Other Pharma | 746 | 699 | 7 | 2 | 230 | - |
| Salick Health Care | 134 | 113 | 19 | 19 | 134 | 19 |
| Astra Tech | 94 | 71 | 32 | 11 | 7 | 40 |
| Marlow Foods | 49 | 55 | (11) | (18) | 2 | 100 |
| Total | 9,171 | 8,658 | 6 | - | 4,432 | (4) |

n/m not meaningful

17

9 SECOND QUARTER PRODUCT SALES ANALYSIS

| | World | | | | US | |
|-------------------|-------------------------|-------------------------|--------------------|-------------------------------|-------------------------|--------------------|
| | 2nd Quarter 2003 \$m | 2nd Quarter 2002 \$m | Actual Growth % | Constant Currency Growth % | 2nd Quarter 2003 \$m | Actual Growth % |
| Gastrointestinal: | | | | | | |
| Losec | 742 | 1,116 | (34) | (39) | 320 | (52) |
| Nexium | 631 | 464 | 36 | 31 | 437 | 25 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | |
|---|--------------|--------------|-------------|-------------|--------------|-------------|
| Others | 17 | 17 | - | (12) | 3 | (40) |
| Total Gastrointestinal | 1,390 | 1,597 | (13) | (18) | 760 | (25) |
| Cardiovascular: | | | | | | |
| Zestril | 118 | 269 | (56) | (61) | 23 | (86) |
| Seloken | 380 | 206 | 84 | 79 | 291 | 112 |
| Atacand | 152 | 129 | 18 | 6 | 35 | (19) |
| Plendil | 129 | 97 | 33 | 26 | 50 | 72 |
| Tenormin | 81 | 96 | (16) | (23) | - | - |
| Crestor | 9 | - | n/m | n/m | - | n/m |
| Others | 98 | 92 | 7 | (6) | 5 | - |
| Total Cardiovascular | 967 | 889 | 9 | 1 | 404 | 3 |
| Respiratory: | | | | | | |
| Pulmicort | 239 | 199 | 20 | 13 | 128 | 51 |
| Rhinocort | 96 | 81 | 19 | 17 | 68 | 24 |
| Symbicort | 127 | 68 | 87 | 61 | - | - |
| Accolate | 25 | 33 | (24) | (27) | 15 | (35) |
| Oxis | 29 | 30 | (3) | (16) | - | - |
| Others | 36 | 37 | (3) | (17) | - | - |
| Total Respiratory | 552 | 448 | 23 | 13 | 211 | 29 |
| Oncology: | | | | | | |
| Zoladex | 213 | 195 | 9 | - | 42 | (24) |
| Casodex | 228 | 148 | 54 | 41 | 72 | 118 |
| Nolvadex | 39 | 117 | (67) | (70) | 5 | (94) |
| Arimidex | 143 | 79 | 81 | 70 | 68 | 94 |
| Iressa | 47 | - | n/m | n/m | 18 | n/m |
| Faslodex | 15 | 8 | 88 | 88 | 15 | 88 |
| Others | 5 | 6 | (17) | (34) | - | - |
| Total Oncology | 690 | 553 | 25 | 15 | 220 | 4 |
| CNS: | | | | | | |
| Seroquel | 270 | 263 | 3 | (1) | 185 | (11) |
| Zomig | 54 | 74 | (27) | (35) | 9 | (76) |
| Others | 7 | 8 | (13) | (38) | - | - |
| Total CNS | 331 | 345 | (4) | (9) | 194 | (21) |
| Pain, Infection and Other Pharma: | | | | | | |
| Diprivan | 98 | 111 | (12) | (17) | 42 | (25) |
| Merrem | 80 | 74 | 8 | 5 | 12 | (29) |
| Local anaesthetics | 122 | 60 | 103 | 90 | 31 | 182 |
| Other Pharma Products | 69 | 112 | (38) | (41) | 14 | (62) |
| Total Pain, Infection and Other Pharma | 369 | 357 | 3 | (2) | 99 | (18) |
| Salick Health Care | 69 | 59 | 17 | 17 | 69 | 17 |
| Astra Tech | 50 | 37 | 35 | 13 | 4 | 33 |
| Marlow Foods | 18 | 27 | (33) | (37) | 1 | - |
| Total | 4,436 | 4,312 | 3 | (4) | 1,962 | (11) |

n/m not meaningful

18

Information for US Investors**RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES**

The profit and loss account and balance sheet set out on pages 10 to 12 are prepared in accordance with generally accepted accounting principles in the United Kingdom (UK GAAP) which differ in certain material respects from those generally accepted in the United States (US GAAP). The differences as they apply to AstraZeneca PLC are explained in the 2002 Annual Report and Form 20-F. The approximate effects on income and shareholders' equity of the GAAP differences are shown below.

| | 1st Half 2003 \$m | 1st Half 2002 \$m |
|--|---|---|
| Income attributable to Shareholders \$m | | |
| Net income for the period under UK GAAP from continuing operations | 1,598 | 1,733 |
| Adjustments to conform to US GAAP | | |
| Purchase accounting adjustments (including goodwill and intangibles): | | |
| - deemed acquisition of Astra (amortisation and other acquisition adjustments) | (461) | (419) |
| - others | 28 | 26 |
| Capitalisation less amortisation of interest | 3 | - |
| Capitalisation less amortisation of software costs | (45) | (42) |
| Deferred taxation | | |
| - on fair values of Astra | 129 | 115 |
| - others | (49) | (83) |
| Pension expense | (16) | (27) |
| Post-retirement benefits/plan amendment | 2 | 2 |
| Share based compensation | (4) | 32 |
| Fair value of derivative financial instruments | (11) | 37 |
| Deferred income recognition | 12 | (47) |
| Unrealised gains on foreign exchange and others | (1) | 4 |
| Net income in accordance with US GAAP | 1,185 | 1,331 |
| Net income per Ordinary Share under US GAAP - basic and diluted | \$ 0.69 | \$ 0.77 |

19

RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES (CONTINUED)

| | 30 June 2003 \$m | 30 June 2003 \$m |
|---|---------------------------------|---------------------------------|
| Shareholders' equity | | |
| <hr/> | | |
| Shareholders' equity under UK GAAP | 12,696 | 10,994 |
| Adjustments to conform to US GAAP | | |
| Purchase accounting adjustments (including goodwill and intangibles): | | |
| - deemed acquisition of Astra | | |
| - goodwill | 13,406 | 12,355 |
| - tangible and intangible fixed assets | 7,658 | 7,737 |
| - others | 114 | 57 |
| Capitalisation, less disposals and amortisation of interest | 241 | 192 |
| Deferred taxation | | |
| - on fair value of Astra | (2,300) | (2,310) |
| - others | (218) | (156) |
| Dividend | 436 | 398 |
| Pension expense | (287) | (189) |
| Post-retirement benefits/plan amendment | (22) | (26) |
| Software costs capitalised | 19 | 68 |
| Fair value of derivative financial instruments | 101 | 87 |
| Deferred income recognition | (2) | (122) |
| Others | 96 | 93 |
| <hr/> | | |
| Shareholders' equity in accordance with US GAAP | 31,938 | 29,178 |
| <hr/> | | |

20

Shareholder Information**ANNOUNCEMENTS AND MEETINGS**

| | |
|---|-----------------|
| Annual Business Review | 2 October 2003 |
| Announcement of third quarter and nine months results | 23 October 2003 |

DIVIDENDS

Edgar Filing: ASTRAZENECA PLC - Form 6-K

The record date for the first interim dividend payable on 6 October 2003 (in the UK, Sweden and the US) is 22 August 2003. Ordinary Shares will trade ex-dividend on the London and Stockholm Stock Exchanges from 20 August 2003. ADRs will trade ex-dividend on the New York Stock Exchange from the same date.

Future dividends will normally be paid as follows:

First interim Announced in July and paid in October

Second interim Announced in January and paid in April.

TRADEMARKS

The following brand names used in this interim report are trade marks of the AstraZeneca group of companies:

Accolate Arimidex Astra Tech Atacand Casodex Crestor Diprovan Exanta Faslodex Iressa Losec Merrem Nexium Nolvadex Oxis Plendil Prilosec Pulmicort Pulmicort Respules Pulmicort Turbuhaler Rhinocort Rhinocort Aqua Seloken Seroquel Symbicort Tenormin Toprol-XL Zestril Zoladex Zomig

ADDRESSES FOR CORRESPONDENCE

| Registrar and Transfer Office | Depository for ADRs | Registered Office | Swedish Securities Register Centre |
|---|--|---|---|
| The AstraZeneca Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA Tel: +44 (0)121 433 8000 | JPMorgan Chase Bank PO Box 43013 Providence, RI 02940-3013 US Tel: (781) 575 4328 | 15 Stanhope Gate London W1K 1LN UK Tel: +44 (0)20 7304 5000 | VPC AB PO Box 7822 S-103 97 Stockholm Sweden Tel: +46 (0)8 402 9000 |

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

In order to utilise the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition; price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; and the risk of environmental liabilities.